Medipharm Labs Corp T.LABS

Technical 420 article

[beaniw]

"A few months ago, Jazz Pharmaceuticals plc (Nasdaq: JAZZ) acquired GW Pharmaceuticals for more than $7 billion and the transaction represented a major milestone for the cannabis industry.

GW was the first company to bring a cannabis-based therapy through US Food and Drug Administration (FDA) clinical trials and proved there are medical benefits associated with cannabis.

The size of the acquisition was eye-popping, and we have been focused on identifying companies that are focused on the biotech side of the cannabis industry. MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) is a Canadian cannabis company that has expanded the business and we are favorable on how the management team has been executing.

MediPharm is Positioned to Record Strong Growth

Although MediPharm’s trend has been to the downside, we believe the business is positioned to record strong growth and are favorable on its leverage to the biotech industry. Earlier this week, MediPharm announced a research partnership master agreement with McMaster University. The relationship is expected to play a key role in the cannabis research and drug development that is being conducted by MediPharm and believe the market does not appreciate the growth prospects that are associated with it.

MediPharm’s cannabis drug license and expertise positions it to supply clinical trial material, assist in investigation protocol and provide regulatory support for multiple trials. Three initial proposed clinical trials will evaluate the effectiveness of proprietary tetrahydrocannabinol (THC) and cannabidiol (CBD) drug candidates for indications that include pain, insomnia associated with major depression, and uremic pruritus.

MediPharm is considered to be a global leader in specialized, research-driven pharmaceutical-quality development and manufacturing of cannabis active pharmaceutical ingredients (API) and derivative products. We are favorable on the amount of value that can be generated through the relationship and will monitor how the story advances from here.

A Growth Story that is Flying Under the Radar

Over the next few months, MediPharm is expected to make additional announcements in regards to specific projects that fall under the agreement as well as the projects that receive support from Health Canada.

At current levels, we believe that MediPharm has a compelling valuation and a favorable risk-reward profile. The company has been quietly executing on the biotech side of the cannabis industry and we are bullish on this aspect of the story.

If you are interested in learning more about MediPharm Labs, please send an email to [e-mail] with the subject “MediPharm Labs” to be added to our distribution list.

For the fastest access to data on MediPharm Labs, sign up for our free newsletter!"

 

[jayc1]

I think market are looking at finacials which have been sinking for quite some time. They will have to sell more porduct, At the moment its diffuclt to see where the increase in revenues are going to come from.

[Righttothetop]

T420 has been a long standing paid supporter of LABS...and saw the same undervalued, high return potential when it was trading at $4....we're now at 0.40c..... Nothing they say is wrong, but for reasons (un)known, LABS just doesn't get any love. So we wait until Tilray gobbles us up or Stada starts selling....at this point, it's pretty much that binary.

[Oceanis]

They are not. Why would you say that they're a paid supporter.  (Wink).  So I took the liberty of a copy/paste, the entire article (attached) and there is no mention that they are shareholders.  See for yourself.  This is a clean article.  Objective. Medipharm Labs Has Been Executing Flawlessly On Its Pharma Strategy EDITORIAL Jun 25, 2021 • 7:33 AM

[Righttothetop]

Apologies....perhaps they only 'WERE' paid....as the contract appears to have run out...but then again....hmmmm......either way, as I said, nothing they have ever mentioned is wrong or bad....just may not be a credible source for newbies is all..... "Pursuant to an agreement between StoneBridge Partners LLC and Medipharm Labs we have been hired for a period of 180 days beginning

[Oceanis]

haha agree entirely except the newbies, this is a great company at a basement price.  as in no brainer.

[Righttothetop]

Man I hope you're right.....and I have agreed with you for years now re: great company....but somehow my faith is always misplaced!! lol Can only hope for the best....

[Oceanis]

it's not going to happen over-night being the nascent industry that it is, but it will happen. One things for sure some of these companies are far stronger than they ever were, at a fraction of the cost/share.  This, and a lot of other ones are strong value for the money, low-risk high-potential at these prices at least.